Live Breaking News & Updates on Advanceddx Biological Laboratories United States

iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies
Anthony Japour, M.D., a seasonedbiotech and pharmaceutical executive with over 30 years of experience, appointed as Chief Executive Officer
Camillo Ricordi, M.D., one of the world s leading scientists in diabetes cure-focused research, cell transplantation and regenerative medicine, appointed as Chief Scientist
SAN MATEO, CA / ACCESSWIRE / June 9, 2021 / iTolerance, Inc
. ( iTolerance or the Company ), a biotechnology company focused on the development of innovative regenerative medicines, today announced the formation of its Executive Leadership Team with the hiring of Anthony Japour, M.D. as Chief Executive Officer and Camillo Ricordi, M.D. as Chief Scientist. ....

United States , Ann Arbor , University Of Miami , Anthony Japour , Jenene Thomas , Camillo Ricordi , Kostenloser Wertpapierhandel , Cameron Gray , University Of Michigan , Cell Transplant Society , National Institutes Of Health , Harvard Medical School , Diabetes Research Institute Federation , Leadership Team , Northwestern University Medical School , International Association For Pancreas , Expert Panel On Transplantation Research , National Diabetes Research Coalition , Diabetes Research Institute Foundation In Miami , Biologic Response Modifiers Advisory Committee , Transplantation Society , American Society Of Transplant Surgeons , Fondazione Cure Alliance , Mediterranean Institute Of Transplantation , Clinical Islet Transplantation Consortium , Islet Cell Resources Icrs Executive Committee ,